Pulmonary Arterial Hypertension

Garo Owens, MD, is president of Gary Owens Associates, and here he discusses optimizing treatment goals for patients with pulmonary arterial hypertension (PAH) while reducing care costs.

Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.

Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).

A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).

Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.

Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons.

Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.

Gary Owens, MD, president of Gary Owens Associates, explains the importance of shared decision making and patient-centered care in pulmonary arterial hypertension (PAH).

Gary Owens, MD, president of Gary Owens Associates, describes mechanisms, trials of treatments in the works for pulmonary arterial hypertension (PAH).

Based on their findings, the researchers of the retrospective study are calling for close evaluation, careful monitoring, and appropriate treatment to mitigate complications and mortality.

Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.

Gary Owens, MD, president of Gary Owens Associates, discusses current treatments available for pulmonary arterial hypertension (PAH) and where future directions in research may lead.

A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).

Gary Owens, MD, president of Gary Owens Associates, outlines the current epidemiological knowledge of pulmonary arterial hypertension (PAH).

A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).

The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.

Panic disorders and specific phobias were the mental disorders most often seen among individuals who have chronic thromboembolic pulmonary hypertension (CTEPH), according to new research.

Levosimendan appeared to increase in-hospital survival rates, although no long-term survival benefit was reported, among patients with comorbid heart failure and connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH).

Drawing on over a decade’s worth of data, new research shows that the 10-year survival of over 9000 patients with idiopathic pulmonary arterial hypertension (IPAH) was 57%.

Based on their findings, the investigators argue a need for more inclusive representation of patients with pulmonary arterial hypertension (PAH) across the weight spectrum.

Repolarization dispersion has been linked to echocardiographic measures of diastolic dysfunction in past research, and a recent study found it potentially indicative of pulmonary arterial hypertension severity.

A recent study found that a selection of non-invasive markers could help identify high-risk children with pulmonary arterial hypertension associated with congenital heart disease.

A small study in northwestern China suggests earlier detection of depression and anxiety in patients with pulmonary arterial hypertension may improve patient quality of life.

Studies focused on Asian populations with pulmonary arterial hypertension (PAH) treated with sildenafil are rare, and a new meta-analysis has found the phosphodiesterase-5 inhibitor effective in this understudied subgroup.

The circulating RNA hsa_circ_0003416 appears to be downregulated in patients with pulmonary arterial hypertension (PAH), according to new research.

This new study aimed to identify metabolic differences in endothelial cells in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (PH) to aid in the development of novel therapeutic approaches.

High-risk patients and patients with a history of pulmonary arterial hypertension (PAH) had significantly different cytokine profiles compared with patients with a low risk of the condition.

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field.

Idiopathic pulmonary arterial hypertension and pulmonary hypertension due to chronic lung disease can be difficult to differentiate, but new research suggests descriptions of lung parenchyma in routine CT scans may prove useful.